Zimmerman and colleagues examined how many depressed patients who scored in the remission range on the 17-item Hamilton Depression Rating Scale (HDRS) did not consider themselves to be in remission ...
Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depressive symptoms in comparison ...
Biohaven shares are flat after the company announced its Phase 2 proof-of-concept study of BHV-7000 failed to meet its ...
US clinical-stage biopharma Biohaven has reported disappointing results from a Phase II proof-of-concept study evaluating BHV ...
Biohaven’s phase 2 proof-of-concept study with BHV-7000 in major depressive disorder fails to meet its primary endpoint: New Haven, Connecticut Monday, December 29, 2025, 13:00 ...
Despite the disappointing primary results, Biohaven noted some positive trends in specific subgroups, particularly among patients with more severe depression at screening and baseline. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback